



3109 N. Triphammer Road  
Lansing, NY 14882  
607.330.2772  
novasterilis.com

Press Release

## **NovaSterilis Inc. and Cornell Researcher Dr. CC Chu Awarded a Metropolitan Development Association Grant**

*ITHACA, October 11, 2010*

NovaSterilis, Lansing NY, and Dr. CC Chu were awarded a grant from the Metropolitan Development Association (MDA) to explore the feasibility of utilizing NovaSterilis supercritical co2 sterilization for a variety of absorbable biomaterials from both commercial and experimental sources.

Dr. Chih-Chang Chu, the Rebecca Q Morgan '60 Professor in the Fiber Science, Dept of Fiber Science & Apparel Design as well as Biomedical Engineering Program at Cornell University, is focused on the development of novel biodegradable biomaterials for the biomedical industry. His work focuses on the design, synthesis and application of both biodegradable "pseudo-proteins" and polysaccharides biomaterials that would have very unusual biological properties such as very low foreign-body induced inflammation as well as supporting natural wound healing to overcome the negative characteristics of current biomaterials. These new biomaterials can be used as the coating for medical devices to reduce or eliminate inflammatory response, wound healing, scaffolds for tissue engineering and drug delivery vehicles.

NovaSterilis Inc, Lansing NY, is committed to the advancement of a supercritical co2 technology platform. NovaSterilis is currently marketing a terminal sterilization technology that achieves a device industry standard Sterility Assurance Level of 10<sup>-6</sup> in many biomedical products and materials. This grant provided the necessary funding for Dr. Chu and NovaSterilis, both innovators in their specific fields, to explore the utilization of supercritical co2 sterilization to overcome issues currently encountered when sterilizing absorbable biomaterials, including residual toxic chemicals or material degradation.

The "The MDA grant was a wonderful opportunity to explore a potential application of NovaSterilis technology and provide strong initial data to apply for additional funding, or pursue a corporate development partner" stated David C. Burns President and CEO NovaSterilis. "The MDA encourages collaborations and provides the incentive to develop new products or processes, this project has the potential to make profound improvements to current and future products, grow our business, and provide additional jobs in Central New York".

### **About NovaSterilis**

NovaSterilis currently markets supercritical carbon dioxide terminal sterilization technologies, and equipment built to support applications of their supercritical carbon dioxide technology platform. The supercritical or fluid phase, of co2 occurs at low pressure (72.9 atm) and moderate temperatures (31.1° C). Supercritical co2 retains advantageous properties of the gas and liquid phases of carbon dioxide making it an ideal fluid for manufacturing processes. The company currently markets the Nova 2200, a 20 liter fully automated supercritical co2 terminal sterilization chamber and is developing an 80 liter unit. NovaSterilis, a privately held biotechnology company located in Lansing New York, is the recipient of a 2007 Presidents Green Chemistry Award presented by the Environmental Protection Agency.

For more information on NovaSterilis and supercritical carbon dioxide visit [www.novasterilis.com](http://www.novasterilis.com)

The foregoing release contains forward-looking statements that can be identified by language such as "produced" and "immediate", for example, or by express or implied statements regarding the value of this technology. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause future results with supercritical carbon dioxide technologies to differ from any previous research. There can be no guarantee that SCCO2 will produce marketed clinical vaccines for sale in any market. Nor can there be any guarantee that the use of SCCO2 to produce therapeutic vaccines will achieve any particular levels of revenue in the future.